1. ChangY, CesarmanE, PessinMS, LeeF, CulpepperJ, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865–1869.
2. GanemD (2010) KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 120: 939–949.
3. MesriEA, CesarmanE, BoshoffC (2010) Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 10: 707–719.
4. CasperC (2011) The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 62: 157–170.
5. AnFQ, FolarinHM, CompitelloN, RothJ, GersonSL, et al. (2006) Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 80: 4833–4846.
6. AshlockBA, MaQ, IsaacB, MesriEA (2014) Productively infected murine Kaposi's sarcoma-like tumors define new animal models for studying and targeting KSHV oncogenesis and replication. PLoS ONE In press.
7. MesriEA, FeitelsonMA, MungerK (2014) Human Viral Oncogenesis: A Cancer Hallmarks Analysis. Cell Host Microbe 15: 266–282.
8. CesarmanE (2014) Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol 9: 349–372.
9. MartinJN (2011) Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and Kaposi sarcoma. Adv Dent Res 23: 76–78.
10. CancianL, HansenA, BoshoffC (2013) Cellular origin of Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus-induced cell reprogramming. Trends Cell Biol 23: 421–432.
11. BrowningPJ, SechlerJM, KaplanM, WashingtonRH, GendelmanR, et al. (1994) Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls. Blood 84: 2711–2720.
12. BarozziP, LuppiM, FacchettiF, MecucciC, AluM, et al. (2003) Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 9: 554–561.
13. MutluAD, CavallinLE, VincentL, ChiozziniC, ErolesP, et al. (2007) In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 11: 245–258.
14. JonesT, YeF, BedollaR, HuangY, MengJ, et al. (2012) Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV. J Clin Invest 122: 1076–1081.
15. RadkovSA, KellamP, BoshoffC (2000) The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 6: 1121–1127.
16. SwantonC, MannDJ, FleckensteinB, NeipelF, PetersG, et al. (1997) Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390: 184–187.
17. GuasparriI, KellerSA, CesarmanE (2004) KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 199: 993–1003.
18. ZhuY, HaeckerI, YangY, GaoSJ, RenneR (2013) gamma-Herpesvirus-encoded miRNAs and their roles in viral biology and pathogenesis. Curr Opin Virol 3: 266–275.
19. CoscoyL (2007) Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat Rev Immunol 7: 391–401.
20. MaQ, CavallinLE, LeungHJ, ChiozziniC, Goldschmidt-ClermontPJ, et al. (2013) A role for virally induced reactive oxygen species in Kaposi's sarcoma herpesvirus tumorigenesis. Antioxid Redox Signal 18: 80–90.
21. BaisC, SantomassoB, CosoO, ArvanitakisL, RaakaEG, et al. (1998) G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391: 86–89.
22. BaisC, Van GeelenA, ErolesP, MutluA, ChiozziniC, et al. (2003) Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 3: 131–143.
23. JensenKK, ManfraDJ, GrisottoMG, MartinAP, VassilevaG, et al. (2005) The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi's sarcoma. J Immunol 174: 3686–3694.
24. SodhiA, ChaisuparatR, HuJ, RamsdellAK, ManningBD, et al. (2006) The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 10: 133–143.
25. WangL, DittmerDP, TomlinsonCC, FakhariFD, DamaniaB (2006) Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res 66: 3658–3666.
26. ChenD, SandfordG, NicholasJ (2009) Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6. J Virol 83: 722–733.
27. ChangHH, GanemD (2013) A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe 13: 429–440.
28. MontanerS, SodhiA, RamsdellAK, MartinD, HuJ, et al. (2006) The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res 66: 168–174.
29. AokiY, TosatoG (2007) Interactions between HIV-1 Tat and KSHV. Curr Top Microbiol Immunol 312: 309–326.
30. BihlF, MosamA, HenryLN, ChisholmJV3rd, DollardS, et al. (2007) Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS 21: 1245–1252.
31. RoyD, SinSH, LucasA, VenkataramananR, WangL, et al. (2013) mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res 73: 2235–2246.
32. MaQ, CavallinLE, YanB, ZhuS, DuranEM, et al. (2009) Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci U S A 106: 8683–8688.
33. LiuR, LiX, TulpuleA, ZhouY, ScehnetJS, et al. (2010) KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood 115: 887–895.
34. CrociDO, SalatinoM, RubinsteinN, CerlianiJP, CavallinLE, et al. (2012) Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 209: 1985–2000.
35. DittmerDP, KrownSE (2007) Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 19: 452–457.
36. NguyenHQ, MagaretAS, KitahataMM, Van RompaeySE, WaldA, et al. (2008) Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22: 937–945.
37. MartinDF, KuppermannBD, WolitzRA, PalestineAG, LiH, et al. (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340: 1063–1070.
38. MoniniP, SgadariC, ToschiE, BarillariG, EnsoliB (2004) Antitumour effects of antiretroviral therapy. Nat Rev Cancer 4: 861–875.
39. StalloneG, SchenaA, InfanteB, Di PaoloS, LoverreA, et al. (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352: 1317–1323.
40. KrownSE, RoyD, LeeJY, DezubeBJ, ReidEG, et al. (2012) Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr 59: 447–454.
41. KoonHB, BubleyGJ, PantanowitzL, MasielloD, SmithB, et al. (2005) Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 23: 982–989.
42. KoonHB, KrownSE, LeeJY, HondaK, RapisuwonS, et al. (2014) Phase II Trial of Imatinib in AIDS-Associated Kaposi's Sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol 32: 402–408.